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Creatine phosphokinaseThe relationships between pharmacokinetic (PK)/pharmacodynamic (PD) indices and outcomeswere investigat-
ed in patients with skin and soft tissue infection (SSTI) who received daptomycin at 4 mg/kg/day. Efﬁcacy was
evaluated in 55 patients from whom Staphylococcus aureus was isolated, with success rates of 94.5% and 69.1%
for clinical and microbiological responses, respectively. The odds ratio for the relationship between the area
under the day 1 concentration–time curve (AUC0–24 h) to the MIC and the probability of clinical success was
1.03 (95% conﬁdence interval [CI] 0.73–1.45), and that for the relationship for probability of microbiological
success was 0.94 (95% CI 0.81–1.09). In 82 patients in the safety analysis, only 1 met the creatine phosphokinase
(CPK) elevation criteria, and this patient'sminimum concentration (Cmin) of plasma daptomycinwas 5.37 μg/mL.
No signiﬁcant relationshipwas found between peak CPK and Cmin (Pearson's correlation coefﬁcient−0.0452). In
conclusion, no clear correlation between PK/PD indices and the probability of efﬁcacy or safety events was dem-
onstrated when daptomycin was administered in SSTI patients using the clinically recommended dosage of
4 mg/kg/day.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Daptomycin (Cubicin®) is a cyclic lipopeptide antibiotic that is ap-
proved for the treatment of skin and soft tissue infections (SSTIs) caused
by gram-positive cocci and of bacteremia caused by Staphylococcus
aureus. Several reports of pharmacokinetic (PK)/pharmacodynamic
(PD) analyses of daptomycin based on an in vivo infection model de-
scribed the ratio of area under the plasma concentration–time curve
to the MIC (AUC0–24 h/MIC) as the PK/PD index associated with efﬁcacy
(Louie et al., 2001; Safdar et al., 2004). However, the magnitude of
AUC0–24 h/MIC associatedwith efﬁcacy based on data from clinical stud-
ies has not been described.
The relationship between daptomycin exposure and creatine phos-
phokinase (CPK) elevation has been reported previously, based on
data from patients who received daptomycin at 6 mg/kg/day for the
treatment of bacteremia or endocarditis (Bhavnani et al., 2010). The341.
1-798456873.
.
. This is an open access article underevaluation of the proposed cut-off points to adverse events, however,
has not been performed in patients receiving daptomycin at
4 mg/kg/day for the treatment of SSTIs. The clinical outcomes of a
phase III study in patients with SSTIs caused by methicillin-resistant
S. aureus (MRSA) or other gram-positive cocci treated with daptomycin
have been reported by Aikawa et al. (2013). Using data from a subpop-
ulation of that study, we investigated the relationships between dapto-
mycin exposure and clinical outcomes in patients with SSTIs who
received daptomycin at 4 mg/kg/day.
2. Materials and methods
2.1. Study design and population for analysis
We analyzed data from a subset population of a phase III study of
daptomycin in Japanese patients with SSTI caused by gram-positive
cocci conducted between 2008 and 2010 (Aikawa et al., 2013). The
studywas reviewed and approved by the ethics committee of each insti-
tution, and written informed consent was obtained from the patients
before enrollment. This study is registered at ClinicalTrials.govthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion of MRSA from specimens obtained within 3 days before starting
treatment or the detection of gram-positive cocci and a suspicion of
MRSA infection and 2) presence of at least 3 of the following: drain-
age/exudate, erythema, ﬂuctuance, localized warmth, pain/tenderness,
swelling/induration, temperature N37.5 °C (oral) or 37 °C (armpit),
white blood cell count outside the normal range, stab cells N15%, pulse
rate N90/min, respiratory rate N20/min, and positive C-reactive protein.
In this study, patients were treated with 4 mg/kg/day intravenous
daptomycin over 30 min for 7–14 days. CPK was measured twice a
week in the treatment period. The population for each analysis was de-
ﬁned as follows: PK/PD analysis population for safety: patients who re-
ceived at least 1 dose of daptomycin and at least 1 blood sample for
plasma concentrationmeasurement; PK/PD analysis population for efﬁ-
cacy: patients who 1) were included in the PK/PD analysis population
for safety, 2) received at least 4 days of treatment, 3) had clinical or mi-
crobiological assessment data at test of cure (TOC), 4) did not receive
any prohibited concomitant antibiotics, 5) did not have important devi-
ations from the protocol, and 6) were infected with S. aureus (methicil-
lin sensitive or resistant). The MIC of daptomycin against S. aureus at
baseline was measured by microdilution methods in accordance with
the Clinical and Laboratory Standards Institute (CLSI) testing guidelines
(M7-A7, 2006).
2.2. PK sampling and measurement of plasma level
Daptomycin was intravenously infused over 30min, and blood sam-
pleswere collected at the following5 timepoints: prior to andat the end
of infusion, 30 min to 2 h, and 4–10 h postadministration on day 4 and
prior to infusion on day 5. Blood was collected in Na–heparin tubes
and stored on ice immediately. Plasma was obtained by centrifugation
at approximately 3000–4000 rpm for 15minuteswithin 2 h of blood col-
lection. The plasma (1.5 mL) was then transferred to a polypropylene
tube, whichwas stored frozen at−20 °C. The daptomycin concentration
wasmeasured at PPD® (Richmond, Virginia, USA). A 300-μL aliquot was
used for reverse-phase high-performance liquid chromatography
(WatersWISP 717 plus)with ultraviolet absorbance detection. Themin-
imum quantiﬁable level was 3.0 μg/mL. The daptomycin standard for
quantiﬁcation was provided by Cubist Pharmaceuticals (Lexington,
MA, USA).
2.3. Population PK modeling
Our analysis included the data from 545 subjects whowere enrolled
in phase I and phase III studies conducted in Japan (127 subjects), which
were reported byDvorchik et al. (2004) (282 subjects), orwhowere en-
rolled in 3 other phase I and phase III studies in non-Japanese (136 sub-
jects). A total of 5586 daptomycin samples for PK (1255 from Japanese
and 4331 from non-Japanese) were included in the data set. Doses
ranged from 2 to 12 mg/kg among the studies described by Dvorchik
et al. (2004) and among the additional 20 studies evaluated. Plasma
concentration data for daptomycin were analyzed using nonlinear
mixed-effects modeling (NONMEM, version 6). The ﬁrst-order condi-
tional estimation with interaction method was used for all analyses.
Our population PK model was further developed in reference to the
published model (Dvorchik et al., 2004). We investigated the inﬂuence
of the covariates reported by Dvorchik et al. (2004), namely, gender,
body weight, temperature, infection status, disease diagnosis, dialysis
and dialysis membrane type, creatinine clearance, and ethnicity, on
daptomycin PK. In addition, a new covariate representing origin, Japan
versus other countries, was also examined.
The ﬁnal population PK model was used to generate the empirical
Bayesian PK parameter estimates. The individual day 1 AUCs were cal-
culated based on simulated daptomycin concentrations. Steady-state
exposures were estimated using the individual empirical Bayes param-
eters. Estimated daptomycin exposure and PK parameters includedminimum concentration (Cmin), AUC0–24 h, weight-adjusted steady-
state volume of distribution (Vss), weight-adjusted clearance (CL),
and half-life (t1/2). The predictability of the model was evaluated using
a visual predictive check. One thousand data sets were simulated for
daptomycin concentrations based on the ﬁnal model. The observed
and simulated data sets in a steady state were each divided into bins
of approximately equal numbers of observations by ranges of time
after dose and then stratiﬁed bydose (4 and 6 mg/kg). For each separate
bin in the observed and simulated data, the 5th, 50th, and 95th percen-
tiles were calculated. The observed data were compared to the 5th,
50th, and 95th percentiles of the observed and simulated data.
2.4. PD endpoints
Clinical andmicrobiological responseswere evaluated at TOC. Clinical
successwas deﬁned as resolution or partial resolution of signs and symp-
toms of SSTI in patients who did not receive additional antimicrobial
agents that could potentially have been effective against the causative
pathogen during the study period. Microbiological success was deﬁned
as “eradication” (admission pathogen absent in culture) or “presumed
eradication” (no material available for culture due to the infection site
being cured or improved). The Independent External Adjudication Com-
mittee (IEAC), consisting of 5 medical experts blinded to study therapy,
reviewed and determined the ﬁnal assessment of efﬁcacy.
CPK elevation represented the safety endpoint of interest, with the
upper limit of normal (ULN) for CPK concentration being deﬁned as
200 U/L. Patients with CPK concentrations meeting either of the follow-
ing conditions were classiﬁed as having elevated CPK: 1) no CPK eleva-
tion at baseline followed by CPK elevations ≥3 × ULN based on 2
sequential measurements during the period from day 4 to 2 days after
the end of therapy, with 1 of 2 CPK elevations ≥5 × ULN or 2) baseline
CPK greater than the ULN followed by CPK elevation ≥5 × ULN based
on 2 sequential measurements during the period from day 4 to 3 days
after the end of therapy (Bhavnani et al., 2010).
2.5. PK/PD analyses
Summary statistics including the geometric mean (GM) and cor-
responding 95% conﬁdence intervals (CIs), minimum, median, and
maximum were provided for PK parameters. Clinical and microbio-
logical responses were summarized by exposure grouped by quar-
tiles. The relationship between response and exposure grouped in
this manner was assessed using Mantel–Haenszel chi-square test.
In addition, logistic regression models with day 1 and steady-state
AUC0–24 h and AUC0–24 h/MIC evaluated as continuous covariates
were used to investigate the effect of exposure on the clinical and
microbiological responses. Similarly, the relationship between CPK
elevation and Cmin grouped by quartiles and as a continuous covari-
ate was evaluated. Pearson's correlation coefﬁcient was calculated
for the relationship between Cmin and peak CPK. SAS version 9.3 for
Windows (SAS, Cary, NC, USA) was used to perform all analyses. All
statistical tests were conducted at the 0.05 signiﬁcance level
(2 sided).
3. Results
3.1. Patient population and daptomycin susceptibility for S. aureus
A total of 82 patientswere included in the PK/PD analysis population
for safety, and 55 patients were included in the PK/PD analysis popula-
tion for efﬁcacy. The patient characteristics for the PK/PD analysis pop-
ulations for safety and efﬁcacy are shown in Table 1. The distribution of
daptomycin susceptibility for S. aureus stratiﬁed bymethicillin-resistant
andmethicillin-susceptible isolates is shown in Table 2. All isolateswere
found to be susceptible to daptomycin according to the CLSI criterion
(1 μg/mL).
Table 1
Baseline demographics in patients whowere included in the PK/PD analyses of safety and
efﬁcacy.
Baseline demographics PK/PD analysis
population for
safety (n = 82)
PK/PD analysis
population for
efﬁcacy (n = 55)
Median age (range) [years] 70 (22–92) 70 (28–92)
Sex male (%) 44 (53.7) 31 (56.4)
Median body weight (range) [kg] 54.0 (29.6–117.8) 53.5 (31.2–108.0)
Median creatinine clearance
(range) [mL/min]
74.7 (31.6–226.1) 73.6 (32.0–226.1)
No. (%) of patients in each
creatinine clearance category
b30 mL/min 0 0
30–50 mL/min 16 (19.8) 12 (21.8)
50–80 mL/min 27 (33.3) 19 (34.5)
≥80 mL/min 38 (46.9) 24 (43.6)
Type of SSTI
Deep skin infection 17 (20.7) 11 (20.0)
Wound, burn, and surgical wound 45 (54.9) 32 (58.2)
Erosion and ulcer 18 (22.0) 11 (20.0)
Others 2 (2.4) 1 (1.8)
Median baseline CPK (range) [U/L] 48.5 (10.0–243.0) 50.0 (10.0–243.0)
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Fig. 1.Visual predictive checks stratiﬁed for (A) 4mg/kg and (B) 6mg/kg doses at a steady
state. The solid red line represents the median observed daptomycin concentrations, and
the solid blue line represents themedian simulated concentrations. The 5th and 95th per-
centiles for observed data are presented with dashed red lines, and 5th and 95th percen-
tiles for simulation data are shown as dashed blue lines. The observed daptomycin
concentrations are represented by circles (●: non-Japanese, ○: Japanese).
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The ﬁnal updated population PKmodelwas a 2-compartmentmodel
with ﬁrst-order elimination, parameterized in terms of CL, central vol-
ume of distribution (V1), intercompartmental clearance (Q), and pe-
ripheral volume of distribution (V2), with intersubject variability
using exponential error models. The following covariates were identi-
ﬁed to be statistically signiﬁcant (P b 0.001): body temperature effect
on CL, sex effect on CL, effect of the IEAC ﬁnal diagnosis subgroup on
CL, creatinine clearance effect on CL nondialysis, infection status effect
on V2, and body weight on Q and V2.
The ﬁnal parameter estimates (mean [%SEM]) were CLnondialysis =
0.823 (2.3) L/h, CLdialysis = 0.264 (5.1) L/h, Q = 3.07 (4.9) L/h, V1 =
5.29 (2.6) L, and V2 = 3.34 (1.9) L, for subjects with median values of
covariates. The ﬁnal parameter estimates are similar to those from
Dvorchik's model, with improved precision. The diagnostic plots
showed a good ﬁt of the ﬁnal population PKmodel to the observed dap-
tomycin concentrations in plasma (Supplementary Figure 1). The pre-
dictive ability of the model was evaluated using the visual predictive
check. Fig. 1 shows the observed data and the lines corresponding to
the 5th, 50th, and 95th percentiles of the simulated data (n = 1000)
for daptomycin. It can be seen that, overall, the ﬁnal PK model for dap-
tomycin predicts the observed concentrations well. PK parameters in
patients who received daptomycin at 4 mg/kg/day are determined
based on the empirical Bayesian PK parameter estimates from the
ﬁnal model as shown in Table 3. The GMs of AUC0–24 h at day 1 and
steady state were 260 μg ∙ h/mL (95% CI 243–278) and 359 μg ∙ h/mL
(95% CI 327–395), respectively.Table 2
Susceptibility of baseline S. aureus isolates to daptomycin for patients in the PK/PD analysis
population for efﬁcacy.
Organisms MIC (μg/mL) Total
≤0.06 0.12 0.25 0.5 1 2
MRSA 0 0 13 31 0 0 44
MSSA 0 0 6 4 1 0 11
MSSA =methicillin-sensitive S. aureus.
Threshold of “susceptible (S)” category in the CLSI interpretive standards for S. aureus is
1 μg/mL.3.3. PD analysis
The duration of daptomycin treatment in the PK/PD analysis popula-
tion for efﬁcacywas 10.5± 3.2 days (range 5–14 days). The clinical and
microbiological response rates were 94.5% (52/55 patients) and 69.1%
(38/55 patients), respectively. Clinical and microbiological responses
by exposure grouped by quartiles are shown in Table 4. For day 1
AUC0–24 h/MIC, there was no relationship between response and expo-
sure grouped by quartiles (P = 0.825 for clinical success and P =
0.429 formicrobiological success). Similarly, no signiﬁcant relationships
were found between day 1 AUC0–24 h and clinical (P=0.758) or micro-
biological response (P= 0.802). On the basis of the logistic regression
model with day 1 AUC0–24 h/MIC as a continuous covariate, the odds
ratio for 100 units was 1.03 (95% CI 0.73–1.45, P = 0.875) for clinical
success and 0.91 (95% CI 0.94–1.09, P = 0.421) for microbiological
Table 3
PK parameters of daptomycin in patients in PK/PD analysis populations for safety and
efﬁcacy.
PK parameter GM (95% CI) Minimum Median Maximum
PK/PD analysis population for safety (n = 82)
Day 1AUC0–24 h (μg ∙ h/mL) 260 (243, 278) 118 264 592
Steady-state AUC0–24 h
(μg ∙ h/mL)
350 (322–381) 86 357 769
Cmin (μg/mL) 5.6 (4.9–6.5) 0.3 6.2 19.5
Cmax (μg/mL) 42.7 (39.8–45.8) 12.8 45.3 72.1
t1/2 (h) 10.8 (10.1–11.5) 4.5 10.7 20.1
Vss (L/kg) 0.177 (0.160–0.181) 0.095 0.165 0.418
CL (mL/h/kg) 11.5 (10.6–12.5) 5.2 11.3 46.8
PK/PD analysis population for efﬁcacy (n = 55)
Day 1AUC0–24 h (μg ∙ h/mL) 260 (243, 278) 118 265 592
Steady-state AUC0–24 h
(μg ∙ h/mL)
359 (327–395) 164 359 769
Cmin (μg/mL) 5.9 (5.0–6.9) 1.2 6.6 19.5
Cmax (μg/mL) 43.2 (40.0–46.7) 17.8 45.3 72.1
T1/2 (h) 11.0 (10.2–11.9) 5.9 10.8 20.1
Vss (L/kg) 0.175 (0.158–0.181) 0.103 0.165 0.418
CL (mL/h/kg) 11.2 (10.2–12.3) 5.2 11.1 24.4
Cmax = maximum plasma concentration at steady state.
Table 5
Evaluation of the relationships between PK/PD indices and clinical or microbiological re-
sponses to daptomycin based on a logistic regression model with a covariate for PK/PD
index.
PK/PD indices Clinical response Microbiological response
Odds ratio (95% CI)
for 100 units
P value Odds ratio (95% CI)
for 100 units
P value
Steady state
AUC0–24 h (μg ∙ h/mL) 1.09 (0.44–2.68) 0.852 0.77 (0.51–1.17) 0.217
AUC0–24 h/MIC 1.02 (0.82–1.27) 0.872 0.91 (0.82–1.01) 0.071
Day 1
AUC0–24 h (μg ∙ h/mL) 1.19 (0.32–4.50) 0.793 1.01 (0.55–1.86) 0.972
AUC0–24 h/MIC 1.03 (0.73–1.45) 0.875 0.94 (0.81–1.09) 0.421
The odds ratios are based on the odds of a successful response for both clinical andmicro-
biological endpoints.
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steady-state AUC0–24 h and clinical or microbiological response when
evaluated using a logistic regression model (Table 5).
Only 1 patient whomet the CPK elevation criteria had a normal CPK
level at baseline (135 U/L) and remained normal on day 7 (48 U/L). The
CPK level increased to 1610 U/L on day 12 (end of treatment [EOT]),
reached 2545 U/L on day 13, and then decreased to normal on day 18
(6 days after the EOT). The Cmin of this patient was 5.37 μg/mL. Overall,
no signiﬁcant relationship was found between peak CPK values and
daptomycin Cmin (Pearson's correlation coefﬁcient−0.0452). The anal-
yses of the relationship between CPK elevation and Cmin grouped by
quartiles and as a continuous covariate were planned, but these analy-
ses were not performed due to only 1 event of CPK elevation.
4. Discussion
Weestablished a population PKmodel by adding data from Japanese
subjects to the data reported by Dvorchik et al. (2004). The ﬁnalTable 4
Clinical and microbiological responses by grouped exposure or PK/PD indices (n = 55).
Exposure or PK/PD index Quartile group Clin
Suc
Steady state
AUC0–24 h (μg ∙ h/mL) 1 164 to b289 12/
2 289 to b359 13/
3 359 to b433 14/
4 433–769 13/
AUC0–24 h/MIC 1 289 to b650 12/
2 650 to b856 14/
3 856 to b1240 13/
4 1240–3076 13/
Day 1
AUC0–24 h (μg ∙ h/mL) 1 118 to b201 12/
2 201 to b265 13/
3 265 to b342 14/
4 342–592 13/
AUC0–24 h/MIC 1 147 to b484 12/
2 484 to b625 14/
3 625 to b848 13/
4 848–2156 13/
The groups of steady-state AUC0–24 h or steady-state AUC0–24 h/MIC were divided by quartiles:
group 3, median to b75th percentile; group 4, 75th percentile to maximum.parameter estimates from our study (CLnondialysis = 0.823 L/h, Q =
3.07 L/h, V1=5.29 L, V2=3.34 L for subjects withmedian values of co-
variates) were similar to those from the previous model (median [per-
cent relative standard error]; CLnondialysis = 0.807 [2.9] L/h, Q = 3.46
[6.3] L/h, V1 = 4.80 [4.2] L, V2 = 3.13 [2.7] L) (Dvorchik et al., 2004).
This model successfully ﬁt the daptomycin concentration–time data in
Japanese, allowing an estimation of daptomycin PK parameters and char-
acterization of the covariates affecting the PK properties of daptomycin.
In our study of patients with SSTIs who received daptomycin at
4 mg/kg/day, GM steady-state AUC0–24 h was 359 (min-max 359–1,
769 μg ∙ h/mL). Similarly, Dvorchik et al. (2004) reported that the medi-
an AUC0–∞ was 339 (min-max 161–1144) μg ∙ h/mL in patients with
gram-positive bacterial infection. In contrast, in a study of healthy sub-
jects, Dvorchik et al. (2003) reported an AUC0–24 h for daptomycin of
494 ± 75 μg ∙ h/mL at day 7, and Hasegawa et al. (2011) reported that
mean AUC0–24 h was 424.7 (95% CI 392.1–460.1) μg ∙ h/mL at day 7.
Based on these results, the AUC0–24 h in patients with infection tended
to be lower than that in healthy subjects. The Cmin in our study
(5.8 μg/mL) was almost identical to the value (5.6 ± 0.8 μg/mL) report-
ed by Hasegawa et al. (2011).
The small number of patients (n = 3) with clinical failure made it
difﬁcult to identify relationships between clinical efﬁcacy and PK/PD in-
dices. Irrespective of looking at the data with AUC or AUC/MIC ratio
evaluated continuously or categorically, there was no evidence of PK-ical response Microbiological response
cess/n (%) P value Success/n (%) P value
13 (92.3) 0.758 9/13 (69.2) 0.596
14 (92.9) 10/14 (71.4)
14 (100.0) 11/14 (78.6)
14 (92.9) 8/14 (57.1)
13 (92.3) 0.825 11/13 (84.6) 0.116
14 (100.0) 10/14 (71.4)
14 (92.9) 9/14 (64.3)
14 (92.9) 8/14 (57.1)
13 (92.3) 0.758 7/13 (53.8) 0.802
14 (92.9) 13/14 (92.9)
14 (100.0) 8/14 (57.1)
14 (92.9) 10/14 (71.4)
13 (92.3) 0.825 10/13 (76.9) 0.429
14 (100.0) 11/14 (78.6)
14 (92.9) 7/14 (50.0)
14 (92.9) 10/14 (71.4)
group 1, minimum to b25th percentile; group 2, 25th percentile to greater than median;
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sponse for which there was a higher percentage of failures. Narrow ex-
posure ranges and/or a narrow MIC range may impede the
identiﬁcation of PK-PD relationships for efﬁcacy. In addition, the diver-
sity of SSTIs (cellulitis, abscess, wound, surgical wound, burn, ulcer,
and decubitus) and the involvement of surgical drainage/debridement
may complicate the analysis of clinical response. For the analysis in
SSTIs, semiquantitative microbiological assessment and/or assessment
of efﬁcacy earlier in therapy may be more suitable to ﬁnd the cut-off
value for efﬁcacy (Food and Drug Administration, 2013).
Using the deﬁnition of Bhavnani et al. (2010), only 1 patient (with a
peak CPK of 2545 U/L) met the criteria for CPK elevation during treat-
ment with daptomycin at 4 mg/kg/day. The Cmin of this patient was
5.37 μg/mL. Conversely, among 108 patients treated with daptomycin
at 6 mg/kg/day for S. aureus bacteremia, Bhavnani et al. (2010) found
6 patients who matched their deﬁnition of CPK elevation, and they re-
ported signiﬁcant relationships between Cmin and AUC and the proba-
bility of CPK elevation. Using classiﬁcation and regression tree
analysis, they reported Cmin ≥24.3 μg/mL as the threshold associated
with increased probability of CPK elevation.We also evaluated CPK ele-
vation according to the deﬁnition of the US labeling recommendation
for the discontinuation of daptomycin treatment: 1) patients with un-
explained signs and symptoms ofmyopathy in conjunctionwith CPK el-
evation to a level N1000 U/L (approximately 5 × ULN) or 2) patients
without reported symptoms who have marked elevation of CPK to a
level of N2000 U/L (approximately 10 × ULN). However, only the same
single patient met these criteria.
To analyze the relationship between CPK elevation and Cmin in pa-
tients treated with daptomycin at 4 mg/kg/day, we conducted analysis
using peak CPK during treatment as a serial variable. No signiﬁcant rela-
tionship between peak CPK and Cmin was found in patients receiving
daptomycin at 4 mg/kg/day (Pearson's correlation coefﬁcient −
0.0452). The main reason for the lack of correlation is considered to be
the lower exposure level. In addition to this, relatively shorter therapy
and twice a week measurement of CPK may cause lack of relationship.
The occurrence of CPK elevation was demonstrated in the ﬁrst
2 weeks in almost all patients (Bhavnani et al., 2010). CPK was evaluat-
ed 3 times per week in the study by Bhavnani et al. (2010). In our study,
Cmin values ranged from 1.2 to 19.5 μg/mL and did not reach the thresh-
old of 24.3 μg/mL reported by Bhavnani et al. (2010).
The incidence of CPK elevation due to daptomycin (4 mg/kg every
24 h) has been reported in comparison with conventional antibiotics
(cloxacillin, ﬂucloxacillin, nafcillin, oxacillin, or vancomycin) in 2 ran-
domized, international trials involving patients with complicated skin
and skin structure infections (Arbeit et al., 2004), and there was no sig-
niﬁcant difference between the treatment groups (2.8% versus 1.8%,
P = 0.26). Considering the low incidence rates together with the low
Cmin level that we described in this report, monitoring the Cmin of dap-
tomycin to investigate the potential risk of CPK elevation in patients re-
ceiving 4 mg/kg/day for the treatment of SSTIs does not appear to be
warranted. These ﬁndings should, however, not discourage routine
CPK monitoring during daptomycin therapy.
Our analyses have some limitations. A limited number of failures to-
gether with a limited exposure range as shown in Table 3 hindered the
ability to identify PK/PD relationships for efﬁcacy. In addition, the MIC
range was limited, and the power was an issue due to limited sample
size for these analyses. In conclusion, based on the results of these anal-
yses, daptomycin exposure in patients with SSTIs treated with dapto-
mycin at 4 mg/kg/day was not associated with clinical or
microbiological outcome. Additionally, the dosage administered didnot reach the critical level associated with CPK elevation. Future PK/
PD analyses based on data frompatientswithMRSA infections receiving
daptomycin over a wider dose range will be useful to better understand
the nature of such relationships.
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